TY - JOUR
T1 - Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma
AU - Porrata, Luis F.
AU - Ristow, Kay
AU - Habermann, Thomas M.
AU - Ozsan, Nazan
AU - Dogan, Ahmet
AU - MacOn, William
AU - Colgan, Joseph P.
AU - Witzig, Thomas E.
AU - Inwards, David J.
AU - Ansell, Stephen M.
AU - Micallef, Ivana N.
AU - Johnston, Patrick B.
AU - Nowakowski, Grzegorz S.
AU - Thompson, Carrie
AU - Markovic, Svetomir N.
PY - 2012/11
Y1 - 2012/11
N2 - The absolute monocyte/lymphocyte count prognostic score (AMC/ALC score) has not been directly compared with the cell of origin (COO) to predict overall survival (OS) and progression-free survival (PFS) in diffuse large B-cell lymphoma (DLBCL). Thus, we retrospectively examined a new cohort of 99 patients with DLBCL treated from 2008 to 2010, (1) to validate whether AMC/ALC score affects survival, (2) to investigate whether AMC/ALC score is independent of COO to predict survival and (3) to assess whether AMC/ALC score can further stratify clinical outcomes by COO. By univariate analysis, the AMC/ALC score was a predictor for OS and PFS. On multivariate analysis performed including the COO and the International Prognostic Index, AMC/ALC score remained an independent predictor for OS and PFS. The AMC/ALC score was able to further stratify DLBCL clinical outcomes by COO. The AMC/ALC score was independent of COO and added to its ability to identify patients with high-risk disease.
AB - The absolute monocyte/lymphocyte count prognostic score (AMC/ALC score) has not been directly compared with the cell of origin (COO) to predict overall survival (OS) and progression-free survival (PFS) in diffuse large B-cell lymphoma (DLBCL). Thus, we retrospectively examined a new cohort of 99 patients with DLBCL treated from 2008 to 2010, (1) to validate whether AMC/ALC score affects survival, (2) to investigate whether AMC/ALC score is independent of COO to predict survival and (3) to assess whether AMC/ALC score can further stratify clinical outcomes by COO. By univariate analysis, the AMC/ALC score was a predictor for OS and PFS. On multivariate analysis performed including the COO and the International Prognostic Index, AMC/ALC score remained an independent predictor for OS and PFS. The AMC/ALC score was able to further stratify DLBCL clinical outcomes by COO. The AMC/ALC score was independent of COO and added to its ability to identify patients with high-risk disease.
KW - Lymphoma and Hodgkin disease
KW - monocyte/lymphocyte prognostic score
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=84867168870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867168870&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.690605
DO - 10.3109/10428194.2012.690605
M3 - Article
C2 - 22551474
AN - SCOPUS:84867168870
SN - 1042-8194
VL - 53
SP - 2159
EP - 2165
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -